Gallacher Capital Management LLC boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 85.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,403 shares of the biopharmaceutical company’s stock after acquiring an additional 5,245 shares during the period. […]